Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00614601 · ClinicalTrials.gov registry record · Phase 2
Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer
A Phase 2 study, sponsored by NewLink Genetics Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00614601: Clinical Trial Phase 2 study, sponsored by NewLink Genetics Corporation.
NCT00614601 is a Phase 2 study that was terminated before completion, run by NewLink Genetics Corporation. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00614601, a Phase 2 study, was terminated before completion, sponsored by NewLink Genetics Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
To assess the response for subjects with pancreatic cancer that have undergone surgical resection and treatment with a vaccine given with or without chemotherapy and chemoradiation.
Interventions
- BIOLOGICAL HyperAcute(R)-Pancreatic Cancer Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-01 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Why NCT00614601 stopped before completion
NCT00614601 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which HyperAcute(R)-Pancreatic Cancer Vaccine is the first listed.
NCT00614601 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00614601 about?
NCT00614601 is a clinical study titled "Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer". To assess the response for subjects with pancreatic cancer that have undergone surgical resection and treatment with a vaccine given with or without chemotherapy and chemoradiation.
What is the current status of trial NCT00614601?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2008-01. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00614601?
The interventions under investigation include: HyperAcute(R)-Pancreatic Cancer Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00614601?
This trial is sponsored by NewLink Genetics Corporation, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00614601's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia